PTCT Ptc Therapeutics Inc

Price (delayed)

$33.27

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.68

Enterprise value

$2.42B

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
The quick ratio has surged by 69% year-on-year and by 9% since the previous quarter
The company's debt fell by 40% YoY
Ptc Therapeutics's equity has shrunk by 95% YoY and by 9% QoQ

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
76.7M
Market cap
$2.55B
Enterprise value
$2.42B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.61
Earnings
Revenue
$927.56M
EBIT
-$503.13M
EBITDA
-$245.3M
Free cash flow
-$85.92M
Per share
EPS
-$7.68
Free cash flow per share
-$1.12
Book value per share
-$11.67
Revenue per share
$12.13
TBVPS
$18
Balance sheet
Total assets
$1.79B
Total liabilities
$2.68B
Debt
$421.44M
Equity
-$893.92M
Working capital
$594.19M
Liquidity
Debt to equity
-0.47
Current ratio
2.03
Quick ratio
1.88
Net debt/EBITDA
0.52
Margins
EBITDA margin
-26.4%
Gross margin
92.9%
Net margin
-62.4%
Operating margin
-53.6%
Efficiency
Return on assets
-36.9%
Return on equity
N/A
Return on invested capital
-68.2%
Return on capital employed
-41.4%
Return on sales
-54.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
0.21%
1 week
7.57%
1 month
-11.68%
1 year
-17.14%
YTD
20.72%
QTD
8.8%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$927.56M
Gross profit
$861.48M
Operating income
-$497.54M
Net income
-$579.22M
Gross margin
92.9%
Net margin
-62.4%
Ptc Therapeutics's revenue has increased by 20% YoY
PTCT's gross profit is up by 19% YoY
The company's net margin rose by 16% YoY and by 7% QoQ
PTCT's operating margin is up by 16% year-on-year and by 11% since the previous quarter

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.61
The EPS is up by 8% since the previous quarter and by 2.8% year-on-year
Ptc Therapeutics's equity has shrunk by 95% YoY and by 9% QoQ
The price to sales (P/S) is 54% lower than the 5-year quarterly average of 5.9 but 5% higher than the last 4 quarters average of 2.6
Ptc Therapeutics's revenue has increased by 20% YoY

Efficiency

How efficient is Ptc Therapeutics business performance
The ROS is up by 18% year-on-year and by 10% since the previous quarter
The ROIC has contracted by 13% YoY but it has grown by 3.5% from the previous quarter
Ptc Therapeutics's ROA has increased by 10% from the previous quarter but it has decreased by 8% YoY

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 33% less than the total liabilities
The quick ratio has surged by 69% year-on-year and by 9% since the previous quarter
Ptc Therapeutics's current ratio has increased by 46% YoY
The company's debt is 147% higher than its equity
Ptc Therapeutics's equity has shrunk by 95% YoY and by 9% QoQ
PTCT's debt to equity has surged by 69% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.